NCT07361887 Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles.
| NCT ID | NCT07361887 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Seville |
| Condition | Atherosclerosis Cardiovascular Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 8 participants |
| Start Date | 2025-11-01 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 8 participants in total. It began in 2025-11-01 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate how moderate wine consumption influences circulating extracellular vesicles (EVs) in healthy adults. EVs are small particles released by cells that carry proteins, lipids, and genetic material, and play important roles in communication between cells. Participants will consume a single serving of red or white wine, and blood samples will be collected before and after consumption to study changes in the composition and function of EVs. The study will also assess how these EVs affect vascular, immune, and brain-related cells. The results are expected to improve our understanding of how moderate wine intake contributes to cardiovascular and brain health.
Eligibility Criteria
Inclusion Criteria * Healthy adult men and women aged 35 to 65 years. * Body Mass Index (BMI) between 18.5 and 29.9 kg/m². * Non-smokers or ex-smokers for at least 12 months. * Moderate alcohol consumers, defined as ≤2 units/day for men and ≤1 unit/day for women. * Normal fasting glucose and lipid profile at screening. * Willing and able to refrain from alcohol, polyphenol-rich foods, and intense exercise for 48 hours before each study visit. * Able to understand the study procedures and provide written informed consent. Exclusion Criteria * History or clinical evidence of cardiovascular, hepatic, renal, thyroid, gastrointestinal, or metabolic diseases (including diabetes, dyslipidemia, or hypertension). * Use of medications or supplements known to affect glucose, lipid, or inflammatory metabolism (e.g., statins, corticosteroids, anti-inflammatory drugs). * Pregnancy or breastfeeding. * Recent blood donation (within the last 3 months) or planned blood donation during the study period. * Major weight change (\>5% of body weight) within the last 3 months. * Participation in another clinical or biomedical study within the previous 3 months. * Known allergy or intolerance to wine, alcohol, or its components (e.g., sulfites). * History of alcohol abuse or inability to abstain from alcohol outside the study context. * Reluctance to receive information about incidental health findings arising from the study. * Any condition judged by the investigators to limit compliance or increase study risk (e.g., psychiatric disorders, inability to adhere to fasting requirements).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07361887 clinical trial?
This trial is open to participants of all sexes, aged 35 Years or older, up to 36 Years, studying Atherosclerosis Cardiovascular Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07361887 currently recruiting?
Yes, NCT07361887 is actively recruiting participants. Contact the research team at delapaz@us.es for enrollment information.
Where is the NCT07361887 trial being conducted?
This trial is being conducted at Seville, Spain.
Who is sponsoring the NCT07361887 clinical trial?
NCT07361887 is sponsored by University of Seville. The trial plans to enroll 8 participants.